Tradestie Institutional Equity Comparison Engine

REGN vs MRNA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

REGN Overall Edge

REGN Captures Institutional Edge (3โ€“1 Pillars ยท 10โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Regeneron Pharmaceuticals Inc (REGN) driven by superior Valuation, Growth & Margin, Options & Structure while MRNA counters with relative strength in Momentum & Technical. Fundamentally, REGN trades at 14.8x Forward P/E with 30.4% operating margin (+36.3% YoY revenue) versus MRNA at 23.0x Forward P/E and -80.8% operating margin (+29.2% YoY). In options structure, REGN sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro) against MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner REGN
REGN 14.8x vs MRNA 23.0x Fwd P/E
Growth & Margin Winner REGN
Op Margin 30.4% vs -80.8% ยท YoY +36.3% vs +29.2%
Momentum & Technical Winner MRNA
1Y +31.0% vs +706.5% ยท 52W Pos 82% vs 67%
Options & Structure Winner REGN
CONSOLIDATION (6th %ile IV) vs CONSOLIDATION (52nd %ile IV)
REGN NASDAQ
Regeneron Pharmaceuticals Inc
Pharmaceutical Preparations
$920.69
-0.29% 1D
Market Cap $95.5B
1M Return +12.4%
1Y Return +31.01%
Forward P/E 14.8x
Unified AI Score
46.0 / 100 HOLD
Tech 29.0 Fund 49.0 Flow 69.0 Mom 56.0
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
1M Return -3.77%
1Y Return +706.45%
Forward P/E 23.0x
Unified AI Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: REGN +31.01% MRNA +706.45% Spread: +675.44 pp (MRNA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period REGN Revenue MRNA Revenue REGN Op. Margin MRNA Op. Margin Margin Edge
FY2018 $5.15B $140M 49.3% -306.0% REGN
FY2019 $6.56B $60M 33.7% -906.8% REGN
FY2020 $8.50B $800M 42.1% -95.0% REGN
FY2021 $16.1B $18.5B 55.7% 72.0% MRNA
FY2022 $12.2B $19.3B 38.9% 48.9% MRNA
FY2023 $13.1B $6.85B 30.9% -61.9% REGN
FY2024 $14.2B $3.24B 28.1% -121.9% REGN
FY2025 $14.3B $1.94B 24.9% -158.1% REGN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: REGN (10) vs MRNA (0)
Institutional Metric REGN MRNA Criterion Row Winner
Market Capitalization Scale $95.5B $80.7B Larger Scale REGN
Trailing P/E Ratio Valuation 20.4x 23.0x Lower Multiple REGN
Forward P/E Ratio Valuation 14.8x 23.0x Lower Multiple REGN
Revenue Growth (YoY) Growth +36.3% +29.2% Higher Growth REGN
Operating Margin (TTM) Profitability 30.4% -80.8% Higher Margin REGN
Net Profit Margin Profitability 28.5% -110.5% Higher Margin REGN
Return on Equity (ROE) Capital Efficiency 14.9% -34.5% Higher ROE REGN
52-Week Range Position Momentum 82% ($592โ€“$992) 67% ($22โ€“$281) Stronger Trend REGN
Beta / 30D Volatility Risk Regime 0.30ฮฒ ยท 55% Vol 2.23ฮฒ ยท 78% Vol Lower Realized Risk REGN
Unified Institutional Score Composite Signal 46.0 / 100 (HOLD) 40.3 / 100 (SELL) Higher Composite REGN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full REGN vs MRNA Buy Guide
REGN CONSOLIDATION
56d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live REGN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MRNA CONSOLIDATION
22d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MRNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither REGN nor MRNA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.